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Development of a Sensitive Wipe-Sampling Procedure coupled to HPLC
Analysis for the Determination of Gemcitabine in Surface Contamination
by Leonard ROSENKRANZ
Monitoring of work surfaces in health-care settings still shows detectable levels of
antineoplastic drugs. The implementation of recent guidelines for the protection of
healthcare workers’ safety and health has already resulted in decreased contami-
nation levels of antineoplastic drugs, although compliance with the recommended
practices is still inadequate. Hence, very sensitive methods for both environmental
sampling and analysis are required to assess the contamination and therefore the risk
of exposure of antineoplastic drugs such as gemcitabine in health-care settings. In
the present study a high-performance liquid chromatography (HPLC) assay for the
sensitive determination of gemcitabine in wipe samples was developed. For sample
concentration and especially cleanup and purification a solid-phase extraction (SPE)
protocol with appropriate buffer solutions was used. A limit of detection (LOD) of
0.091 µg/ml was obtained. To assess the developed analytical method, surface wipe
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1.1 Aim of this Thesis
Cancer is the second leading cause of death worldwide, being responsible for 8.8 mil-
lion deaths in the year 2015. With the incidence expecting to increase by about 70 %
over the next two decades, the importance of the disease as a global health problem
will increase even further [1]. As of today, therapeutic strategies can be divided into
several core pillars: Surgery, Radiotherapy, Chemotherapy, Targeted Therapy and
Immunotherapy. Chemotherapy is the application of one or more cytotoxic drugs
to reduce tumor size and induce remission/prolong the life of the patient. A wide
variety of pharmacological agents have been used over the years to treat different
kinds of cancer, from the earliest non-specific drugs like sulfur mustard to modern
targeted therapies via antibodies like Trastuzumab. Since not every type of cancer
allows for treatment by targeting specific antigens or metabolites, traditional cyto-
static approaches (that target common and unspecific mechanisms of cell division
like DNA synthesis) are still the norm today for most cases [2].
Given their toxic nature, many substances widely used for treatment possess a se-
rious hazard potential for the environment and healthcare workers. Individuals at
increased risk for drug exposure are nursing staff, pharmacists, physicians, oper-
ating room personnel but also shipping and receiving personnel [3]. Workplace
exposure to antineoplastic drugs (e.g. through skin contact or alveolar uptake by
inhalation) can cause a series of adverse health effects such as infertility, skin rashes,
and possibly other malignancies (e.g. leukemia) [4]. There are multiple strategies
to protect healthcare workers at risk. First, proper protective equipment during the
preparation, administration, and disposal of antineoplastic drugs is crucial. Second,
administrative controls and protocols have to be established in order to minimize the
potential risk of exposure in healthcare settings [5]. Hence, sensitive and specific an-
alytical methods are required to establish pharmaco-/toxicosurveillance in the work
place. Since the risk of unwanted exposure correlates with surface contamination
during the preparation and administration of antineoplastic drugs, many analytical
methods aim to detect hazardous agents in workplace surfaces [6]. Wipe sampling
is a versatile and widely used method to assess surface contamination.
This study focuses on the development of an analytical method for the accurate de-
tection of small amounts of gemcitabine in surface wipe samples. Gemcitabine is a
hydrophilic chemotherapeutic agent mainly used for the treatment of solid tumors
like breast cancer, ovarian cancer, non-small cell lung cancer, and pancreatic can-
cer. The developed analytical method combines an isocratic reversed-phase high-
performance liquid chromatography (HPLC) with a prior solid-phase extraction for
the concentration of the analyte and also reduction of matrix interferences.
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1.2 Occupational Hazards of Antineoplastic Drugs
Nowadays, antineoplastic drugs are a cornerstone in the therapy of cancer. In 1943,
Alfred Gilman and Louis Goodman performed their therapeutic studies with nitro-
gen mustard in mice, and laid the foundation for modern chemotherapy in medicine
[7]. In the following years, many more substances were discovered and used to treat
cancer, beginning with antifolates (methotrexate) in 1948 and 5-fluorouracil in 1957,
up to the discovery of cisplatin in 1978 [8–10]. While initially considered as a ther-
apeutic breakthrough, several disadvantages of antineoplastic drugs soon became
apparent. Due to their unspecific toxicity, they pose a substantial occupational haz-
ard for healthcare workers [2].
In the 1970s, it was discovered that urine samples of healthcare workers who were
involved in the preparation, administration, or disposal of antineoplastic drugs showed
higher levels of mutagenic substances, chromosomal aberrations and sister chro-
matid exchanges compared to nonexposed workers [11–13]. Additionally, acute
effects of occupational exposure to antineoplastic drugs have been well described,
such as skin rashes, nausea, hair loss, abdominal pain, nasal sores, as well as chronic
effects [14]. These effects include the reproductive system, for example spontaneous
abortion [15], genotoxic changes [16], and cancers [14, 17]. More recent studies sug-
gest that even staff members without direct patient contact, such as unit clerks, ward
aides, dieticians, and shipper/receivers, are at risk of contamination when cytotoxic
substances are used within a hospital setting [18]. In summary it has become clear
that occupational exposure should be limited to ensure worker’s safety in health
care.
Following the findings stated above, guidelines for the safe handling of hazardous
drugs were established in the US in 1985 by the American Society of Health-System
Pharmacists, followed by the Oncology Nursing Society, the National Institutes of
Health, and the Occupational Safety and Health Administration. These guidelines
were updated and expanded in 1995 [19]. In Germany, workplace safety is cov-
ered by a dual system composed of the federal trade supervisory boards (Gewerbe-
aufsichtsämter) and the employers’ liability insurance associations (Berufsgenossen-
schaften). Established guidelines were updated in 2009 and are in accordance with
national and EU law. Since there is no accepted safe level of exposure [20], all official
documents stress the significance of workplace monitoring of contaminations with
ADs, regardless of the amount of cytotoxic substances being handled.
Different types of exposure have been studied in the past, the most important ones
being dermal, inhalative, and oral/gastrointestinal. Since ingestion is relatively un-
likely to occur in an occupational setting, analytical methods had to be developed for
the measurement of surface and airborne concentration of cytotoxic substances [18].
Surface wipe sampling in combination with different methods of detection (liquid
chromatography/gas chromatography and UV/VIS spectrometry/mass spectrome-
try/tandem mass spectrometry) has been a standard practice to monitor work place
contamination with cytotoxic agents for many years [21, 22].
1.3 Gemcitabine
Gemcitabine is a cytostatic drug used for the treatment of a variety of cancer types.
Worldwide, it is the third most widely used prescription drug in clinical oncology
[23]. In the US, the Federal Food and Drug Administration (FDA) has approved
gemcitabine for the first-line treatment of advanced or metastasized non-small cell
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FIGURE 1.1: Chemical structure of gemcitabine
lung cancer and pancreatic cancer in 1996. The approval has been expanded in the
years 2004 and 2006 to encompass metastatic breast cancer and advanced ovarian
cancer respectively [24]. In Germany, similar approvals exist for gemcitabine.
1.3.1 Pharmacodynamics
The pharmacology of gemcitabine is well understood [23, 25]. Chemically, it belongs
to the group of pyrimidine analogues, more specifically, the fluorinated cytidine ana-
logues (Figure 1.1), where both hydrogens at the 2’ position of deoxycytidine are
replaced by fluorine. Gemcitabine is a weak base with a pKb of 10.4, and is soluble
in water and methanol [26]. From a pharmacodynamic point of view, gemcitabine
is as an antimetabolite, which inhibits DNA synthesis through several intracellular
targets (Figure 1.2). After administration and cellular uptake via sodium-dependent
and -independent nucleoside transporters (due to its hydrophilic nature), the pro-
drug is phosphorylated by deoxycytidine kinase (DCK) to its mono-, di- and triphos-
phate forms. The active triphosphate is incorporated into DNA by DNA polymerase
alpha and leads to "masked chain termination" [27]. Upon incorporation of fur-
ther deoxynucleotide triphosphate (dNTP) after gemcitabine triphosphate, common
DNA repair mechanisms by 3’5’-exonuclease are inhibited [28]. Therefore, this pro-
cess is called "masked chain termination" (Figure 1.3). The "masked chain termina-
tion" subsequently leads to cessation of DNA synthesis, and subsequently cell death
[27].
Another target is ribonucleotide reductase, which catalyses the reaction of cytidine
diphosphate to deoxycytidine diphosphate and provides necessary components for
DNA synthesis. Activated gemcitabine diphosphate binds to ribonucleotide reduc-
tase (RR) and thus inhibits this reaction. Since subsequently less conventional com-
ponents for DNA are provided, the likelihood of the incorporation of gemcitabine-
triphosphate into the DNA is increased. Additionally, deoxycytidine triphosphate
acts as an inhibitor of DCK, which leads to a self-potentiation mechanism of gemc-
itabine, by its inhibition of RR [23, 25, 28, 29].
Another important pathway leading to tumor cell death is caspase signaling. With
regard to caspase signaling, gemcitabine functions as a p38 mitogen-activated pro-
tein kinase (MAPK) activator. MAPK triggers apoptosis by arbitration of MAPK-
activated protein kinase (MK2) [30]. MK2 leads to phosphorylation of heat shock
protein Hsp27, which acts as a chaperone during cell growth. Cells with phospho-
rylated Hsp27 are not able to replicate correctly [31].
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1.3.2 Pharmacokinetics
After uptake and distribution, around 90% of intracellular gemcitabine are rapidly
metabolized by cytidine deaminase (CDA), which is expressed in high levels in
plasma and liver tissue, into the primary metabolite 2’,2’-difluoro-deoxyuridine (dFdU).
dFdU itself is cytotoxic and acts as a radiosensitizer [32]. It makes DNA more
vulnerable to the effects of radiation. This leads to a synergistic effect when com-
bining gemcitabine with radiotherapy. Another less important pathway of intra-
cellular metabolisation is inactivation through dephosphorylation of gemcitabine
monophosphate by 5’-nucleotidases. From an extracellular perspective, due to its
hydrophilic nature, around 10% of the drug are eliminated by kidney without prior
metabolisation. The main metabolite dFdU is also hydrophilic, and thus subject to
renal filtration. Both substances are eliminated independently of dose over the lin-
ear range, but proportional to creatinine clearance. In doses between 40 mg/m2 to
3650 mg/m2, plasma levels of gemcitabine peak after 15 to 30 minutes. Higher doses
result in nonlinear pharmacokinetics [33]. Plasma clearance is rapid, with a plasma
half-life (t(1/2)) of 5 to 20 minutes. After 24 hours, more than 75% of gemcitabine has
been metabolized and excreted. In contrast, dFdU is eliminated less rapidly and can
be detected in significant concentrations (1 µmol/L) up to one week after adminis-
tration [34].
FIGURE 1.2: Pathways of gemcitabine transport, metabolism, and
sites of action [25]
1.4 Analytical Detection and Quantification Methods for Gem-
citabine
A variety of analytical methods for the detection and quantification of gemcitabine
have been described in literature. In order to determine very low concentrations of
gemcitabine sensitive analytical techniques are required. Commonly used analytical
methods are accelerator mass spectrometry (AMS) [35] and liquid chromatography-
mass spectrometry (LC–MS/MS). AMS is well known for its high sensitivity and
specificity. However, the low availability and use of radiolabeled drugs makes this
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FIGURE 1.3: Masked chain termination by gemcitabine triphosphate
[28], deoxynucleotide triphosphate is designated as dNTP, gemc-
itabine triphosphate as dFdCTP, and gemcitabine diphosphate as
dFdCDP
technique expensive. LC-MS/MS is a suitable method with limits of detection in the
picogram per milliliter range without the application of radioactive labeling [36].
The methods of choice for the quantification of environmental wipe samples are
LC-MS/MS and HPLC methods. An overview of the applied LC/MS-MS methods
and HPLC methods for the detection and quantification of gemcitabine in surface
wipe samples in literature is shown in Table 1.1. Van Nuland et al. recently de-
veloped and validated an ultra sensitive method for the simultaneous quantifica-
tion of gemcitabine and its metabolite 2’,2’-difluoro-deoxyuridine in human plasma
by LC–MS/MS [36]. The samples were prepared with solid phase extraction. The
validated assay ranges from 2.5–500 pg/ml for gemcitabine and 250–50,000 pg/ml
for dFdU. A simple wipe sampling procedure coupled to LC-MS/MS analysis was
developed for simultaneous determination of ten cytotoxic drugs including gemc-
itabine [21]. Another analytical approach for the quantification of gemcitabine is
GC-MS/MS [37]. However, HPLC and MS methods are rather time consuming
and expensive. In contrast, UV spectrophotometric methods are a time saving and
rapid alternative. Menon et al. developed a simple, rapid, and cost effective UV
spectrophotometric method for the determination of gemcitabine HCl in bulk drug
and pharmaceutical formulations. Gemcitabine reacts with gold nanoparticles and
changes their original red colour to dark blue as a result of aggregation. The ini-
tial absorbtion maximum is shifted from 522 nm to 688 nm. A limit of detection of
0.44 µg/ml was found [38]. However, due to the lack in sensitivity, the UV spec-
trophotometric method may not be appropriate for the detection of gemcitabine in
wipe samples. Additionally, for the analysis of complex matrices a prior extraction
process has to be implemented. Besides UV spectrophotometry, fluorescence spec-
troscopy has been successfully applied to quantify gemcitabine with a LOD of 3 to
100 mmol/l. The method is based on the fluorescence quenching of functionalized
gold doped quantum dots by gemcitabine via photoinduced charge transfer [39].
Further rapid and versatile analytical methods for the quantification of gemcitabine
are immunoassays. For this purpose, a monoclonal antibody was functionalized to
polystyrene nanoparticles to develop a homogenous agglutination inhibition assay.
Compared to LC-MS/MS methods, immunoassays typically lack sensitivity [40].
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TABLE 1.1: Overview of analytical methods for the detec-
tion/quantification of gemcitabine in surface wipe samples
Analytical
Method




LC-MS/MS, [21] wipe sample n.a. 0.1 ng/cm2
LC-MS/MS, [41] wipe sample 0.125 ng/cm2 0.25 ng/cm2
LC-MS/MS, [42] wipe sample 0.10 ng/ml 0.2 ng/ml
LC-MS/MS, [43] wipe sample 0.0020 ng/ml 0.0068 ng/ml
LC-MS/MS, [44] wipe sample n.a. 0.5 ng/ml
HPLC/UV, [45] plasma/urine n.a. 50 ng/ml / 20
µg/ml
LC-MS/MS, [46] urine 0.05 µg/l 0.2 µg/l
HPLC-DAD, [47] plasma 0.10 µg/l 0.20 µg/l
HPLC/UV, [48] plasma n.a. 20 µg/ml
1.5 High Performance Liquid Chromatography
Chromatography describes an analytical technique, which is applied for the sep-
aration, detection, and quantification of specific substances. Hereby, the compo-
nents are distributed between two phases: stationary phase and mobile phase [49].
High performance liquid chromatography (HPLC), which is a special form of Liquid
Chromatography (LC), is the most widely used form of chromatography for soluble
analytes. Whereas LC is a general term and describes any chromatographic proce-
dure in which the mobile phase is a liquid (other examples being open column and
thin layer chromatography), HPLC enhances the performance (hence "High Perfor-
mance") of LC principles, by optimizing key factors of the method. In conventional
open column LC, the solvent containing the analytes is applied onto a column con-
sisting of large particles (~150 - 250 µm) and gravity is used to guide the mobile
phase through the stationary phase. After passage of the mobile phase, the solvent is
analyzed and separated analytes can be detected after certain intervals of time. Sep-
aration occurs as consequence of the distribution of the analytes between the mobile
and stationary phases (and their different affinities for both of them) [50]. Figure 1.4
displays an overview of the technique. There is a huge variety of chromatographic
principles, such as adsorption, partition, ion exchange, and size exchange.
However, basic LC has several disadvantages: (1) low resolution due to relatively
large particle size; (2) slow procedure and operator dependent results; (3) high costs,
one column is used for one analysis. HPLC overcomes these problems by introduc-
ing a reusable column, containing a stationary phase packed with small particles (~2
- 50 µm), and using pumps to apply high pressure within the chromatographic cir-
cuit, to improve resolution and speed up the process [51].
Figure 1.5 gives a schematic overview of a HPLC workstation. A HPLC pump trans-
ports the mobile phase forward through the injection loop. There, the sample con-
taining the analytes enters the mobile phase and the mixture is pumped through
the HPLC column (usually within a column heater) containing the stationary phase.
Separation results during transport by the mobile phase as the analyte interacts with
the stationary phase in a different way than the other components of the matrix
through varying principles, depending on the applied column and composition of
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the mobile phase. After separation, the mobile phase containing the distinct analytes
enters a detector. Commonly used detectors are UV detectors or mass spectrometers.
1.5.1 Separation
HPLC utilizes different principles to separate an analyte from its matrix. All prin-
ciples are based on the interaction between the analyte, and the mobile/stationary
phase. Table 1.2 provides an overview of the most commonly applied separation
techniques by HPLC and their associated retention mechanisms. By deliberate se-
lection of a specific stationary phase and a corresponding mobile phase, different
retention mechanisms can be used to separate analytes. Furthermore, different prin-
ciples can be combined, as was the case during the experiments performed for this
thesis (combination of Ion Exchange and Ion Pair chromatography).
TABLE 1.2: Overview of chromatographic principles [51]
Chromatographic principle Mechanism of retention
Adsorption Surface adsorption on basis of polarity.
Ion Exchange chromatography Charge interaction between solute ions and
counter ionophores on packing.
Ion Pair Ions in solution are paired or neutralised and
separated as an ion pair on a reversed-phase col-
umn.
Size exclusion Filtering effect on the basis of hydrodynamic
volume.
Chiral Diastereoisomeric interactions between solute
enantiomers and chiral sites within the packing.
Affinity Bio-specific binding of solute to immobilised
ligand.
FIGURE 1.4: Principle of Liquid Chromatography [B.M.Tissue1996]
1.5.2 Mobile and Stationary Phase
The mobile phase in HPLC consists of one or more liquid chemicals, used to trans-
port and interact with the analyte of a given assay. For Reversed-phase HPLC, most
mobile phases have a hydrophilic base (adjusted to a specific pH by buffers), com-
bined with varying percentages of more hydrophobic components such as methanol
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FIGURE 1.5: Overview of HPLC Instrumentation [laboratory-
info.com/hplc]
or acetonitrile [52]. Another widely used possibility is the continuous adjustment
of thecomposition of the mobile phase by applying gradient pump systems. In the
case of ion pair chromatography, which is used during this thesis, the mobile phase
was altered by the addition of an ion pair reagent. This reagent subsequently binds
to the charged analyte, and forms an uncharged complex which can in turn interact
with the stationary phase [53].
HPLC stationary phases consist of columns with varying length and diameter
and packings therein. Typical columns are stainless steel lined with glass to with-
stand high pressure and to prevent metal catalysis of solvent-solute reactions within.
Packings come in different forms. Generally, the particle size of the spherical sup-
ports used to pack a column has a crucial impact on the performance of the HPLC
column. The smaller the particle size, the better the separation of the analyte due
to the higher surface area and therefore the higher number of theoretical plates in a
given column. Hence, the particle size is usually kept ≤ 5 µm [54, 55]. The choice
of packing material results in the mode of separation within the column (see above).
The majority of widely used packings consist of microporous silica based particles,
which can be chemically modified. Three types of derivatisation are common:
Hydrocarbon Groups Long (C18H37) or short (C2, C8, etc.) chain hydrocarbons re-
sult in a hydrophobic surface area and are used in Reversed-Phase HPLC.
Polar Groups Amino, ether, diol and cyanopropyl groups present a polar surface
area, used for Normal Phase HPLC.
Ion Exchange Groups Quarternary ammonium, sulphonic acid, etc., used for Ion-
Exchange Chromatography.
A special form of derivatisation is the use of chiral compounds, in chiral chro-
matography. By utilizing substances like cyclodextrines or chiral polysaccharides
with R- or S-configuration, a racemic analyte can be separated into its diastereoiso-
mers. Separation occurs because diastereoisomeric forms of the analyte interact dif-
ferently with the chiral compounds of the stationary phase[51].
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1.5.3 Detectors
After separation, the desired analyte is detected by a suitable device. The list below
provides a short summary of the most common detectors in HPLC [50, 56].
Ultraviolet/Vis/Photo Diode Array Light absorbing properties of electrons within
a molecule at particular wavelengths are used. Light of a specific wavelength
passes through a glass tube containing the analyte. Electrons in that molecule
absorb the light and thus change its intensity. The flexibility of UV detectors
can be enhanced by using a photo diode array, and scanning several wave-
lengths simultaneously. Figure 1.6 illustrates an UV/Vis detector coupled with
a photodiode array.
Fluorescence Specific analytes possess the ability to emit fluorescent light after ab-
sorbing radiation at a longer wavelength. If an analyte is not capable of fluores-
cence, it may be chemically modified by coupling to a fluorescing compound.
Generally, fluorescent detectors are more selective and sensitive than UV de-
tectors, as they don’t measure a small difference in intensity of absorbed light,
but rather an intensity compared to a baseline of zero.
Electrochemical Analytes usually contain a number of functional groups. Many
of them can be oxidised or reduced by applying an electric potential greater
than the analytes half-wave potential. An electrochemical detector uses a fixed
potential and monitors the changes in its current. When an analyte passes
through and is oxidised/reduced, a change in this current occurs and detection
is possible.
Refractive Index Solutes change the refractive index of a mobile phase. By compar-
ing two cells, one purely filled with mobile phase and the other one containing
mobile phase and the analyte, detection can be achieved. The main advan-
tage of a refractive index detector is its broad spectrum: all substances can be
detected, regardless of their chemical composition. However, its sensitivity is
inferior to that of an UV detector.
Evaporative Light Scattering The mobile phase containing the analyte is nebulized
and evaporated into fine particles. A laser beam is subsequentially used and
the scattered radiation after hitting the particles is measured. Depending on
concentration, every non-volatile analyte can be detected as it scatters the laser
radiation.
Mass Spectrometry Mass spectrometry measures the mass-to-charge ratio of an ionised
analyte. After separation by HPLC, the analyte enters an ion source and is
ionized by a variety of methods (electron ionization, chemical ionization, pho-
toionisation, spray ionisation, etc.). The charged particles are subsequently
detected by utilizing their electro-magnetic properties (ion trapping, time of
flight, quadrupole filters, etc.).
1.5.4 Internal Standard
Internal standardisation is a technique used in chromatography to improve accuracy
of an analysis. A constant amount of internal standard is added to each analyzed
sample, and the ratio of analyte to internal standard is calculated. A calibration
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FIGURE 1.6: Principle of Diode Array Detector ( c©Agilent Technolo-
gies): Visible light emitted by the tungsten lamp and UV light emitted
by the deuterium lamp pass the flow cell and is subsequently detected
by the diode array.
curve, containing known amounts of analyte with fixed amounts of internal stan-
dard per calibration sample can be obtained. Subsequently, the initial amount of
analyte in the sample of interest can be calculated. Especially in methods utilizing
several steps of sample preparation, which may result in a certain loss of analyte, an
internal standard can be useful for correction. However, the internal standard has to
meet following requirements [57]:
Similar Structure The structure of an internal standard has to be as similar as possi-
ble to the analyte of interest, ensuring similar retention times, extraction char-
acteristics, detectability, etc.
Well resolved For HPLC the internal standard has to exhibit a distinct chromato-
graphic signal without interference from the analyte.
Not present in sample An internal standard may never be inherently present in the
sample of interest.
Detectable The internal standard has to be detectable and quantifiable, but not nec-
essarily at the same detection parameters.
Stability The internal standard has to be stable during sample preparation and
chromatographic analysis.
1.5.5 Optimization of Separation and Detection
To optimize separation and detection, several parameters of a HPLC method can be
modified [58]:
Mobile Phase Composition and therefore affinity of the analyte towards the mobile
phase can be modified and optimized. Additionally, gradient systems, which
contain several different mobile phases at varying concentrations throughout
an analytic run, can be applied.
Stationary Phase Different stationary phases and various principles of separation
(normal-phase, reversed-phase, ion exchange, adsorption, etc.) are available.
In addition to that, particle size and surface area also affect separation.
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Detector Method of detection can be optimized, choosing from a wide array of
available detectors (ultraviolet photometry, mass spectrometry, refractive in-
dex monitoring, photo diode arrays, optical rotation, etc...).
Flow Rate has a crucial effect on separation by influencing the time of analyte inter-
action between the stationary and mobile phase. Flow rate also plays an impor-
tant role in potential upscaling of the method for obtaining a high throughput
method.
Temperature directly affects mass transfer and viscosity of the analyte and mobile
phase. Higher temperatures may improve peak resolution, but also may result
in a decrease in specificity.
1.6 Solid Phase Extraction
1.6.1 Overview and Principle
Solid Phase Extraction is a form of Liquid Chromatography (LC), which is typically
used for the extraction of analytes from complex matrices. This technique enables
the isolation (extraction), clean up, as well as the concentration of the analytes prior
to their identification or quantification [59]. In principle, a typical SPE protocol in-
volves four steps: 1. Conditioning the packing, 2. Applying (loading) the sample,
3. Washing the packing (removal of interferences), 4. Eluting and recovering the
analyte [60]. In the following section these steps are described in detail. Figure 1.7
provides an overview of the technique.
FIGURE 1.7: Working steps in Solid Phase Extraction Chromatogra-
phy; Sample Components: A = Analyte(s) of interest, W = Weakly re-
tained, undesired matrix component(s), X = Intermediate undesired
matrix component(s), Z = Strongly retained undesired matrix com-
pontent(s); Solvents: C = Conditioning solvent, D = Equilibration
solvent, L = Loading solvent, W = Washing solvent, E = Eluting sol-
vent [61]
1. Conditioning the packing: First, the column package is conditioned by pas-
saging solvent through the SPE column in order to remove any present im-
purities (e.g. from manufacturing). Second, the conditioning of the column
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allows the sorbent to be solvated, which may decrease the sample retention.
Solvation is especially important for reversed-phase silica-based packings.
2. Applying (loading) the sample: Next, the analyte is dissolved in a weak sol-
vent, designated as "L", and carefully applied ("loaded) on the SPE column.
Usually, a column material with a high affinity for the analyte is used, to quan-
titatively bind the substance to the stationary phase. By using the weak solvent
the applied analyte is strongly retained. As a weak solvent water or a buffer is
used for reversed phase SPE (RP-SPE). In contrast, for ion exchange SPE a sol-
vent with very low ionic strength should be used. The flow-rate of the sample
loading can easily be adjusted by varying the vacuum.
3. Washing (Rinsing): In the washing step, the cartridge is carefully washed with
a solvent of intermediate strength ("W") in order to remove interfering sub-
stances. An extensive washing step should be avoided, since this may result
in a partial elution of the analyte and thus a decreased analyte recovery. Usu-
ally, the rinsing step should be stopped before the analyte starts to leave the
cartridge to avoid any loss of the analyte. Typical washing solutions are water
or buffer. The addition of a small amount of organic solvents contributes to the
removal of hydrophobic substances.
4. Eluting: Finally, for the quantitative elution of the desired analyte an elution
solution with a higher affinity to the stationary phaseis used, which elutes
the analyte [62]. During the elution step the analyte is eluted and collected.
Hereby, the analyte should be collected in a solvent volume which is as small
as possible to allow a sensitive detection of the analyte. This can be achieved
by using a strong elution solvent (E). However, an intermediate strength elu-





2.1.1 List of Materials
• High Performance Liquid Chromatography (Shimadzu, Duisburg, Germany)
– Double LC-20 AD pumps, gradient unit
– UV-VIS SPD 20 AV detector
– CTO-10 AC column oven
– Class-VP 7 HPLC software suite
• Mixed-Mode Cation-Exchange SPE, MCX 3cc, 60mg (Waters, Eschborn, Ger-
many)
• Thermo Accucore XL C18 HPLC Column, 150mm/ID4.6mm/Particle Size 4
µm (ThermoFisher Scientific, Schwerte, Germany)
• LiChrospher RP-18 HPLC Column, 25cm/ID4.6mm/Particle Size 5 µm (Merck,
Darmstadt, Germany)
• Supelcosil LC-18 HPLC Column, 15cm/ID4.6mm/Particle Size 3 µm (Merck,
Darmstadt, Germany)
• Vapotherm Evaporator (Barkey, Leopoldshöhe, Germany)
• Ika HS260 basic Shaker (Ika, Staufen, Germany)
• Hettich Universal 32 Centrifuge (Hettrichlab, Tuttlingen, Germany)
• Analytical Balance (Sartorius Lab Instruments, Göttingen, Germany)
• 50 mL Round-Neck Bottles (Omnilab, Munich, Germany)
• Gemcitabine Hydrochloride ≥ 98% (Merck, Darmstadt, Germany)
• 2’-Deoxycytidine ≥ 99% (Merck, Darmstadt, Germany)
• Adenosine ≥ 99% (Merck, Darmstadt, Germany)
• Hydrochloric Acid 37% (Merck, Darmstadt, Germany)
• Sodium Hydroxide ≥ 97% (Merck, Darmstadt, Germany)
• Sodium Dihydrogen Phosphate (Merck, Darmstadt, Germany)
• Methanol anhydrous, 99.8% (Merck, Darmstadt, Germany)
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• Acetonitrile anhydrous, 99.8% (Merck, Darmstadt, Germany)
• Fluka Phosphoric Acid for HPLC, 85-90% (ThermoFisher Scientific, Schwerte,
Germany)
• Millipore Ultrapure Lab Water (in-lab purification system)
List of buffers:
Acidified Water: 1 mL 4% Phosphoric acid (v/v), deionized water ad 100 mL
SPE Washing buffer (50 mM NaH2PO4, pH = 2.9): 3.5 g NaH2PO4, 200 µl H3PO4
85%, deionized water ad 500 ml
SPE elution buffer: 2 mL NH4OH, MeOH ad 100 mL
2.2 Methods
2.2.1 Preparation of Standard Solutions
Stock solutions of gemcitabine and the internal standard 2’-deoxycytidine were pre-
pared in methanol at a concentration of 10 µg/ml. The stock solutions were stored at
4 - 8 ◦C up to 1 week. Working solutions were created by diluting the stock solution
to obtain final concentrations of 0.01 to 1.0 µg/ml for the analyte.
2.2.2 Surface Wipe Sample Preparation
For sampling, a new set of clean, disposable, powder-free gloves was used to avoid
any contamination. First, three cellulose filters (grade 391, Sartorius) were moist-
ened with 6 drops Millipore water each. An area of 20 x 20 cm2 was wiped, ac-
cording to a previously mentioned wiping scheme (Figure 2.1) [22]. Different areas
(table, scale, floor, sink, hood etc.) were tested, each in triplicates. Real samples were
taken at an oncological outpatient clinic in Munich. The filters where then placed in
a glass vial and frozen at −20 ◦C for long-term storage. Before testing, the filters
were thawed and 20 ml of acidified water, containing 4 % of phosphoric acid, was
added . The filters were then shaken at 180 rpm on a horizontal shaker for 20 min.
15 ml of this solution was concentrated by solid phase extraction as described below.
Blank samples without wiping were prepared analogously.
FIGURE 2.1: Wipe Scheme of analyzed surface
2.2.3 Solid Phase Extraction (SPE) in Wipe Samples
Our SPE-Method used cation exchange columns, which were primed with 2 mL
MeOH followed by 2 ml NaH2PO4 buffer solution (pH = 2.9). After priming, the
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working solutions of gemcitabine and the internal standard were pipetted onto the
column. A mild vacuum was applied until the columns ran dry. Then, washing
steps were performed, starting with 2 mL washing buffer, followed by 2 mL MeOH.
It has to be noted that columns were allowed to run dry only after the application of
buffer. After each washing step, samples were collected and analyzed analogously
by our HPLC method. Finally, analyte and internal standard were eluted with a so-
lution of 1 ml of 2% NH4OH in MeOH.
Subsequently, samples were concentrated on a tempered water bath at 50 ◦C N2 at-
mosphere. 100 µl 4% H3PO4 was subsequently added. Samples were analyzed by
RP-HPLC.
2.2.4 Final Standard Operating Procedure
The filter was wetted with 20 mL acidified water and shaken for 20 minutes on a
laboratory shaker. Subsequently, an aliquot of 15 ml was used for each experiment.
For the following solid phase extraction, up to five SPE columns were processed
simultaneously using a 5 - port vacuum manifold. The columns (MCX 3cc, 60mg
Waters) were pretreated with both 2 ml MeOH and 2 ml SPE washing buffer (50 mM
NaH2PO4, pH = 2.9) to ensure the desired acidic pH value for the sample. 25 µl of
the internal standard (10 µg/ml in water) was added to the column. Consequently,
the sample (15 mL) was processed through the SPE column until running dry. The
SPE columns were thoroughly washed with 2 mL SPE washing buffer and 2 mL
methanol. Then, the sample was eluted by adding 1 mL of 2 % ammonium hydrox-
ide in methanol. The sample was concentrated at 50 ◦C under nitrogen flow. After
the concentration step, the dried compounds were dissolved in 100 µl of phosphoric
acid and gently mixed for several minutes. The sample was consequently analyzed
with RP-HPLC. For quantification of gemcitabine a standard curve of gemcitabine
solutions ranging from 0 - 2.5 µg/ml was performed. HPLC method parameters are
listed in Table 2.1 below.
TABLE 2.1: Parameters of RP HPLC-Method
Column Thermo Accucore XL C18 (150 mm / ID 4.6 mm / Particle
Size 4 µm)
Solvent CH3CN:MeOH:NaH2PO4buffer (pH=3), 5:5:90, + octane-
sulfonate sodium 11 mM
Detection wavelength 275 nm







3.1 Preliminary Testing of a RP-HPLC Method for the Detec-
tion of Gemcitabine
To analyze the basic chromatographic properties of gemcitabine various solutions
with concentrations of gemcitabine ranging from 0.5 to 10 µg/ml were directly in-
jected into the HPLC system and measured by RP-HLPC. The initial parameters of
the described method were adapted from Rahul et al. [26] with minor deviations
and are summarized in Table (Table 3.1). Using these conditions, initial HPLC runs
were performed and improved systematically.
TABLE 3.1: Parameters of preliminary HPLC-Method
Column LiChrospher RP-18 HPLC Column,
25cm/ID4.6mm/Particle Size 5 µm
Solvent CH3CN:H2O, 10:90
Detection wavelength 275 nm
Injection volume 25 µl
Temperature 35 ◦C
Flow 1.2 ml/min
TABLE 3.2: Preliminary analysis of different gemcitabine concentra-
tions (n=3)




0.5 28,014 676 (2.4%)
1 56,565 517 (0.9%)
2 100,042 1,498 (1.5%)
5 240,696 17,223 (7.1%)
10 449,819 10,959 (2.4%)
As shown in Figure 3.1, a sharp gemcitabine peak was observed at a retention time
of 3 minutes. Hence, the compound eluted quickly showing Gaussian peak shape
with good peak symmetry (asymmetry factor= 1.02). It was possible to detect 12.5
ng gemcitabine per injection with an average peak area of approximately 28,000.
Measurements were performed in triplicates.
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FIGURE 3.1: Exemplary chromatogram of gemcitabine (5 µg/ml)
FIGURE 3.2: Standard curve of gemcitabine stock solutions by RP-
HPLC. Standard deviations (n=3) are displayed as error bars.
Additionally, Figure 3.2 displays a standard curve obtained by measuring different
concentrations of gemcitabine.
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3.2 Development of a RP-HPLC Method for the Detection of
Gemcitabine
Next, an ion pairing reagent (IPR) was added to optimize chromatographic behav-
ior of the analyte by increasing its retention time. Furthermore, different internal
standards were tested to improve the precision of the method. All experiments were
initially performed out of stock solutions in absence of filter matrix interference, or
wipe sample impurities to optimize the method under the best possible conditions.
3.2.1 Internal Standards
Simultaneously to the early IPR experiments, the addition of internal standards was
analyzed in order to improve the precision of the analytical method. Therefore, the
chemically similar internal standards adenosine and 2dC (as described by [63]) at
a concentration of 2 µg/ml were added. The concentration of gemcitabine was set
to 2 µg/ml, while the rest of the parameters of the method were kept constant, as
displayed above. For comparison, the influence of both the analyte and the internal
standards on mean peak area and retention time was evaluated. As shown in Ta-
ble 3.3, the internal standard 2dC was eluted at 4.8 minutes, whereas adenosine was
eluted at 3.7 minutes. The retention time of gemcitabine was at 8.1 minutes. Due to
possible early eluting pollutants or matrix components in the real sample, the inter-
nal standard 2dC with the higher retention time of 4.8 minutes was chosen for our
method.
TABLE 3.3: Chromatographic Parameters of Internal Standards and
Gemcitabine, c=2 µg/ml, n=3
Parameter Gemcitabine 2’-Deoxycytidine Adenosine
Mean Peak Area 100,042 ± 1.5% 322,282 ± 2.2% 145,548 ± 2.3%
Mean Retention Time 8.1 ± 1.1 min 4.8 ± 0.4 min 3.7 ± 0.6 min
3.2.2 Addition of Ion Pair Reagent (IPR)
An IPR was used to increase the retention of gemcitabine and allow its detection in
a real sample also containing interfering contaminants. The chosen IPR was sodium
1-octanesulfonate. To evaluate the effect of the added IPR, the influence on retention
time of gemcitabine was analyzed. Consequently, the IPR sodium 1-octanesulfonate
was added to the mobile phase at pH 3. Parameters of the RP HPLC method are
shown in Table 3.4. In addition to the IPR, the column type was changed to the
shorter column Thermo Accucore XL C18 in order to decrease the HPLC analysis
time. The mobile phase was changed to a triphasic mixture, as previously described
by [63].
3.2.3 Influence of IPR Concentration
Next, the influence of the IPR sodium 1-octanesulfonate on the RP-HPLC method
was evaluated. For this study, different concentrations of octanesulfonate sodium (1
mM, 3 mM, 11 mM) were added to the mobile phase at pH 3 and analyzed with var-
ious concentrations of gemcitabine (0.1, 0.5, 1, 10 µg/ml) and the internal standard
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TABLE 3.4: Parameters of RP HPLC-Method
Column Thermo Accucore XL C18 (150 mm / ID 4.6 mm / Particle
Size 4 µm)
Solvent CH3CN:MeOH:NaH2PO4buffer (pH=3), 5:5:90, + octane-
sulfonate sodium 3 mM
Detection wavelength 275 nm
Injection volume 25 µl
Temperature 35 ◦C
Flow 1.2 ml/min
2dC (10 µg/ml). Therefore, all other parameters of the RP HPLC method were kept
constant (Table 3.4).
TABLE 3.5: Influence of different IPR concentrations on retention of
gemcitabine and 2dC. Averaged retention times (n=3) are displayed.
Concentration of IPR
(mol/L)




1 7.5 ± 0.1 11.3 ± 0.1
3 11.7 ± 0.2 16.4 ± 0.1
11 18.5 ± 0.5 27.7 ± 1.3
By adding 1 mM, 3 mM, and 11 mM of IPR, retention times for 2‘-deoxycytidine
of 7.5 minutes, 11.7 minutes and 18.5 minutes were obtained (Table 3.5). Addition-
ally, higher concentrations of the IPR of 1 mM, 3 mM, and 11 mM analogously in-
creased the retention time of gemcitabine from 11.3 minutes to 16.4 minutes and 27.7
minutes, respectively. However, peak symmetry deteriorated with decreasing IPR
concentrations with peaks showing an increment in tailing. For following experi-
ments, the highest concentration of 11 mM sodium octanesulfonate was applied for
our method. To improve analysis speed with the higher retention times, a shorter
chromatographic column (Thermo Accucore XL C18, 150mm / ID4.6mm / particle
size 4 µm) was used, which resulted in retention times of 9 min for gemcitabine and
6 min for 2dC.
3.2.4 Influence of Absorption Wavelength
In this study, the influence of the absorption wavelength on the developed RP-HPLC
method for gemcitabine was evaluated. Samples of the analyte and the internal
standard 2dC with a concentration of 10 µg/ml were analyzed at two different ab-
sorption wavelengths (267 nm; 275 nm) by RP-HPLC. As shown in (Table 3.6), a
detection wavelength of 267 nm shows a mean peak area (gemcitabine) of approx-
imately 395, whereas the absorption wavelenghts of 275 nm resulted in a slightly
higher main peak area of 443. The same effect can be seen for the internal standard
2dC. 275 nm was used for detection wavelength throughout the following studies.
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TABLE 3.6: Influence of Absorption Wavelength on mean peak area
Wavelength (nm) Mean peak area gemc-
itabine (10 µg/ml)




The influence of several parameters on the retention times and mean peak areas of
gemcitabine such as absorption wavelengths, type and concentration of IPR, and
selection of internal standards were investigated during the stepwise method opti-
mization. A limit of detection of 0.091 µg/ml was obtained.
A summary of all optimized parameters is listed in Table 3.7.




Ion pairing reagent sodium 1-octanesulfonate, c = 11 mM
Detection wavelength 275 nm
HPLC column (Thermo Accucore XL C18, 150mm /
ID4.6mm / particle size 4 µm
Mobile phase CH3CN:MeOH:NaH2PO4 buffer
(pH=3), 5:5:90
Injection volume 25 µl
Column temperature 35 ◦C
Flow 1.2 ml/min
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3.3 Analysis of Gemcitabine in Wipe Samples
3.3.1 Wipe Sample Preparation
As described in chapter 2, sample acquisition was performed by collecting wipe
samples. Therefore, a specific wipe scheme (Figure 2.1) was applied. For the ex-
periments, the desired surface area was selected, and wiped with three folded filter
papers previously wetted with six drops of ultrapure water. After sample acquisi-
tion, the filters were stored in a 50 mL round neck bottle and frozen at −20 ◦C until
analysis. Due to the high water solubility of gemcitabine, the extraction solvent was
deionized water. Before analysis, samples where thawed at room temperature. Sub-
sequently, 20 mL of acidified water were added in order to extract gemcitabine from
the filter matrix (see chapter 2). For method optimization, different filter materials
and pH values of the extraction solution were considered and analyzed.
3.3.2 Influence of Filter Matrix on Interference
For sampling, the surface of interest has to be wiped with a wet filter paper to absorb
any environmental gemcitabine. The solvent is subsequently added to the filter to
quantitatively extract the gemcitabine from the filter. Not only gemcitabine, but
also components of the filter matrix itself may be co-extracted by this procedure. In
order to assess the extraction of inherent components of the filter matrix, different
filter papers were prepared according to the established procedure for the analyte,
without the addition of gemcitabine or the internal standard. First, filter discs grade
391 from Sartorius were tested.
FIGURE 3.3: Chromatogram of an extract from Sartorius filter paper,
prepared with the established procedure without analyte or internal
standard
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The retention time of gemcitabine with the established method was between 8
to 9 minutes. A prominent signal was present at 6 minutes, which is in direct vicin-
ity to the retention time of the internal standard 2dC. Consequently, various filter
materials were assessed to examine the interference between filter material and ana-
lyte as well as internal standard. Second, Whatman grade 42 ashless filter paper for
instrumental analysis was evaluated.
FIGURE 3.4: Chromatogram of an extract from Whatman filter paper,
prepared with the established procedure without analyte or internal
standard
As shown in Figure 3.4, the chromatogram clearly displays a prominent signal
at 6 minutes. At a retention time of 6 minutes, the internal standard was detected.
Additionally, the background noise was increased compared to the Sartorius filter
material. Thus, the Whatman filter paper was not appropriate for our developed
method. Lastly, a third filter paper was examined to reduce the high interference
signal at 6 minutes. The third examined filter paper was a Schleicher& Schuell 589
round filter disk. Similar to the Whatman filter, a high background noise was promi-
nent. Additionally, the strong signal at 6 minutes was similarly present. Sartorius
filter papers were used for further studies.
3.3.3 Influence of pH Value of Filter Extraction Solution
Quantitative extraction of gemcitabine from the filter is a crucial part of sample
preparation. Three different aqueous solutions, acidic water at pH 3, distilled water
at pH 6, and alkaline water at pH 9 were prepared. The pH of the solutions was
adjusted by the addition of either H3PO4 4% (v/v) or NH3 2% (v/v). Then, standard
sample preparation was executed and three different samples, containing 40 ng gem-
citabine were analyzed. In order to compare the aqueous solutions, the influence on
the mean peak area of gemcitabine, which represents the amount of gemcitabine in
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FIGURE 3.5: Chromatogram of an extract from Schleicher& Schuell
filter paper, prepared with the established procedure without analyte
or internal standard
the sample, was analyzed. As shown in Figure 3.6, all three aqueous extraction so-
lutions showed a similar peak area, the mean peak area being 279,347 with a RSD of
0.99%. For further experiments, we chose an aqueous acidic extraction solution with
a pH of 3.
3.3.4 Extraction of Gemcitabine in Wipe Samples by Solid Phase Extrac-
tion (SPE)
Prior to each RP-HPLC analysis, a SPE process was performed for extraction of gem-
citabine. For our experiments, working solutions of gemcitabine (0.1 µg/ml) and
internal standard (2 µg/ml) were prepared and directly measured by our HPLC
method. To evaluate the recovery of gemcitabine after SPE, solutions of the analyte
and internal standard at the same concentration with a prior SPE extraction pro-
cess were analogously analyzed. Additionally, all washing eluates were measured
to evaluate potential losses of analyte or internal standard during the washing steps.
The recovery of gemcitabine after SPE was calculated according to Equation 3.1.
Main peak area of gemcitabine after SPE extraction
Mean peak area of gemcitabine
= Recovery (%) (3.1)
No visible peaks of gemcitabine or internal standard could be detected in any
of our washing solutions (blank spectrum not shown). The achieved recovery of
gemcitabine after SPE was 98.32 % (Table 3.8).
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FIGURE 3.6: Influence of various aqueous extraction solvents on gem-
citabine mean peak area (4 µg/ml)
TABLE 3.8: Recovery Rate: Stock Solution vs SPE Eluate
(cgemcitabine=0.1 µg/ml, n=3)
Mean Area Stock Mean Area SPE Eluate Recovery Rate in %
12,498.7 ± 10.68 % 12,288.7 ± 17.63 % 98.32
3.3.5 Influence of pH Value of SPE Eluate
After optimization of the SPE, the influence of the pH value on the chromatographic
parameters of the wipe sample was investigated. As previously described, before
injection in the HPLC system, all samples were reconstituted in mobile phase, and
different concentrations of H3PO4 were added to obtain various pH values in the so-
lutions. To compare the influence of the pH value of the sample (SPE eluate) on the
RP-HPLC method for gemcitabine, both peak area and peak symmetry were com-
pared at various pH values of the mobile phase.
Figure 3.7 and Figure 3.8 show sample chromatograms at different pH values rang-
ing from pH 1 to pH 7. At pH 1, gemcitabine showed a deformed signal at 8.4 min
with a mean peak area of 56,856. 2dC appeared at 5.3 min with a mean peak area of
194,415. Peak symmetry of gemcitabine was 0.78 and for 2dC 1.2.
At pH 3, gemcitabine showed a distinct signal at 8.4 min with a mean peak area of
247,162. 2dC appeared at 5.3 min with a mean peak area of 326,817. Peak symmetry
of gemcitabine was 1.2 and for 2dC 1.3.
At pH 5, gemcitabine showed a deformed signal at 8.4 min with a mean peak area of
56,856. 2dC remained a distinct signal at 5.3 min with a mean peak area of 194,415.
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pH = 1 pH = 3
FIGURE 3.7: Chromatograms of gemcitabine and 2’-dC at different
pH values
Peak symmetry of gemcitabine was 0.8 and for 2dC 1.3.
Finally at pH 7, gemcitabine signal lost most of its intensity at a retention time of 8.3
min with a mean peak area of 8,004. The 2dC signal appeared heavily deformed at
5.3 min with a mean peak area of 363,473. Peak symmetry of gemcitabine was 1.1
and for 2dC 0.68. Consequently, for further method development, SPE samples were
adjusted to a pH value of 3 prior to HPLC analysis.
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pH = 5 pH = 7
FIGURE 3.8: Chromatograms of gemcitabine and 2’-dC at different
pH values
3.3.6 Summary
In summary, the RP-HPLC method for the quantitative detection of gemcitabine in
wipe samples was successfully developed. The standard protocol for the wipe sam-
ple preparation as well as a SPE process prior to each RP-HPLC measurement was
established in order to extract the analyte as well as to concentrate the gemcitabine
sample to increase the assay sensitivity (volumetric concentration factor: 200). With
regard to possible contaminations during sampling on the surface and the filter ma-
trix, the influence of several parameters such as filter material, pH value of filter
extraction solution, and pH value of SPE eluate was investigated during the step-
wise method optimization.
A summary of all optimized parameters is listed in Table 3.7.
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3.4 Outpatient Clinic Surface Measurements
To verify our developed analytical method in a real working environment, wipe
samples were taken at a clinic for oncology and measured according to the devel-
oped SOP.
3.4.1 Sample Acquisition and Results
Wipe sample acquisition was performed on site as described in Chapter 2. Hereby,
three filters per site were used and stored until further use. After SPE, the samples
were analyzed by our developed RP-HPLC method. A standard curve of gemc-
itabine solutions ranging from 0 - 2.5 µg/ml was performed in order to quantify the
amount of gemcitabine in an outpatient oncolocy clinic (Figure 3.9). A correlation
coefficient of 0.99 was obtained.
An exemplary chromatogram overlay of real wipe samples containing gemc-
itabine at different sample acquisition sites in an outpatient oncology clinic is shown
in Figure 3.10. A clear and distinct gemcitabine peak at the retention time of around
8.2 minutes was visible. The overview of sample acquisition sites and results are
shown in Table 3.9 .
As shown in Table 3.9, samples "Bathroom Floor" (2), "Patient Recreation Area" (3) and
"Cytostatic Isolator" (6) contained quantifiable traces of gemcitabine with a maximum
of 3.98 µg/ml of the anti-neoplastic drug.
Traces of gemcitabine could also be detected in the patient recreation area (c = 0.2935
µg/ml) and the patient bathroom floor (c = 0.0622 µg/ml). In work benches, printer,
floors and the reception desk of the outpatient clinics, the analyte concentration was
below the LOD and therefore was designated as not detected.
TABLE 3.9: Sample Acquisition Sites and Concentrations in a Outpa-
tient Oncology Clinic
Site No Site cgemcitabine (µg/ml) mgemcitabine (ng/cm2)
1 Reception desk n.d. –
2 Patient bathroom floor 0.0622 0.0207
3 Patient recreation area 0.2935 0.0978
4 Work bench 1 n.d. –
5 Work bench 2 n.d. –
6 Cytostatic isolator 3.9797 1.3266
7 Printer n.d. –
8 Floor n.d. –
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FIGURE 3.9: Standard curve of gemcitabine calibration solutions by
RP-HPLC for outpatient samples
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FIGURE 3.10: Chromatogram overlay of wipe samples at different




4.1 Preliminary Testing of a RP-HPLC Method for the Detec-
tion of Gemcitabine
The first aim of this thesis was to develop a RP-HPLC method for the quantitative
analysis of gemcitabine. Preliminary tests adapting HPLC parameters with minor
deviations from a previously published method [26] were conducted. Since param-
eters such as temperature, column length and material, pH value of solvent, and de-
tection wavelength have a great influence on method sensitivity and specifity, HPLC
runs were performed and improved systematically. Our results showed that gemc-
itabine can be both rapidly and quantitively detected by RP-HLPC in the range from
0.5 µg/ml to 10µg/ml. However, the low retention time of gemcitabine at only three
minutes was a major challenge. Since the higher aim of this thesis was to detect and
quantify the analyte gemcitabine in real wipe samples, early eluting hydrophilic im-
purities, either from filter matrix or surface contaminants, could easily interfere with
the desired analyte peak. Hence, a longer retention time (> 10 min) is essential to an-
alyze gemcitabine without any matrix interference.
4.2 Development of a RP-HPLC Method for the Detection of
Gemcitabine
4.2.1 Internal Standards
In order to improve the precision and accuracy of our analytical method an inter-
nal standard was applied. 2’-deoxycytidine and adenosine were selected, since both
compounds are chemically similar compounds to gemcitabine and are therefore ex-
pected to exhibit similar chromatographic characteristics. As shown in the figures
below (Figure 4.1) and (Figure 4.2), all substances share the chemical backbone of
a (deoxy)ribonucleoside, modified by a di-fluoro group in the case of gemcitabine.
Whereas the analyte and 2’-deoxycytidine are both conjugated to the base cytosine,
adenosine is conjugated to the base adenine.
Our results showed, that the internal standard adenosine was eluted at 3.7 min and
2’dC at 4.8 min compared to gemcitabine at 8.1 minutes. The peaks were perfectly
separated and showed no overlapping effects.
Due to early eluting pollutants or matrix components in real wipe samples, the in-
ternal standard 2dC with the higher retention time of 4.8 minutes was chosen for our
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2’-deoxycytidine Adenosine
FIGURE 4.1: Chemical Structure of Internal Standards
FIGURE 4.2: Chemical Structure of Gemcitabine
method. Experiments indicated that chromatographic signals (peak area and reten-
tion time) stayed consistent during the time of analysis. Hence, it can be concluded
that internal standards were stable under storage conditions.
In summary, the RP-HPLC method for the quantitative detection of gemcitabine
as pure substance was successfully optimized. The aims were to achieve an in-
creased retention time to avoid interference with early eluting pollutants and to
achieve appropriate mean peak areas, which allows a quantitative detection of gem-
citabine.
4.2. Development of a RP-HPLC Method for the Detection of Gemcitabine 33
4.2.2 Addition of Ion Pair Reagent (IPR)
After the preliminary chromatographic experiments, a further optimization of the
analytical method was performed. Since the retention time of native gemcitabine
was too short for adequate detection of gemcitabine in a real wipe sample also con-
taining early eluting contaminants, an ion-pairing reagent was applied [63–65]. The
aim was to increase the retention of gemcitabine for effectively separating the matrix
components and wipe sample impurities from the analyte peak. Additionally, the
sensitivity of detection can be increased by the application of an ion pairing reagent.
Since sodium octanesulfonate was successfully used by Khatri et. al for the detec-
tion of gemcitabine in human plasma by RP-HPLC [63], sodium octanesulfonate was
also chosen as IPR in this study. The interaction of the polar compound gemcitabine
with the non-polar surface of the stationary phase appeared to be too low and gem-
citabine consequently eluted out immediately without much retention at 3 minutes.
Gemcitabine is a weak base with a pKb of 10.4, which is predominantly protonated
at pH 3, and is thus an excellent target for ion pairing at pH 3. The anion of the ion
pairing reagent (octanesulfonate sodium), octanesulfonate, binds to the protonated
positively charged analyte and forms a non-ionic compound via ionic interactions
and thus increases the hydrophobicity of gemcitabine. As a result, the affinity of
the gemcitabine-octanesulfonate ion-pair to the stationary phase of the column is
increased and, as a consequence, the analyte interacts stronger with the stationary
phase and its retention time increases.
Depending on the concentration of the IPR, the retention of the analyte can be in-
creased [65]. Both peak symmetry and signal intensity may significantly differ de-
pending on IPR concentration.
4.2.3 Influence of IPR Concentration
As shown by our study, increasing the concentration of the IPR octanesulfonate
sodium from 1 mM to 11 mM in the mobile phase clearly led to an increase of the
retention times of both the internal standard and the analyte gemcitabine. The re-
tention time of 2’-dC could be increased up to 18.5 minutes at an IPR concentration
of 11 mM in the mobile phase.
The reason for the increased retention time can be attributed to the increased hy-
drophobicity of analyte-IPR or internal standard-IPR. Hydrophobic substances show
a higher affinity to the stationary RP-Phase and the retention times increase [65].
Since higher concentrations of octanesulfonate sodium resulted in an improved peak
symmetry and a longer retention time of both internal standard and gemcitabine, a
concentration of 11 mM of the IPR octanesulfonate sodium was used for our further
experiments. By applying this concentration, retention times of 27 minutes for gem-
citabine and 18 minutes for 2’dC were achieved.
With the increased retention time a better separation of gemcitabine and internal
standard from filter matrix components and wipe sample impurities could be ob-
tained. Nevertheless, due to long retention times, the chromatographic column
was eventually switched to a shorter type, a Thermo Accucore XL C18 (150mm /
ID4.6mm / particle size 4 µm) in order to guarantee a rapid analytical detection
method for gemcitabine. By applying the shorter HPLC-column retention times of 9
min for gemcitabine and 6 min for 2’dC were obtained, which proved to be satisfac-
tory for further experiments.
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4.2.4 Influence of Absorption Wavelength
Absorption wavelength may have a significant influence on sensitivity of detec-
tion of analytes during HPLC chromatography. Therefore, two different absorption
wavelengths (267 nm and 275 nm) were tested for our RP-HPLC method. In liter-
ature, 267 nm is commonly used in methods for detection of gemcitabine [63, 64].
Our study showed, that the detection wavelength of 275 nm was more beneficial
since higher mean peak areas could be obtained. Thus, 275 nm was used as detec-
tion wavelength for our method.
4.3 Analysis of Gemcitabine in Wipe Samples
The higher aim of this thesis was the quantitative detection of gemcitabine in real
wipe samples. On the basis of our previous results of the detection of pure gemc-
itabine, the method in real wipe samples was stepwise established and optimized.
After the chromatographic conditions of our method were successfully tested, fur-
ther experiments on preanalytics were performed. Preanalytics consists of two phases,
sample acquisition via wipe-sampling and extraction. As extraction method a SPE
approach was chosen. Our goal was to quantitatively collect gemcitabine on sur-
faces and to further extract the analyte from possible contaminants prior to HPLC
analysis.
4.3.1 Influence of Filter Matrix on Interference
An important aspect for the method development is the selection of the optimal filter
material. The appropriate filter material should not interfere with the analyte or the
internal standard and be chemically inert to solvents used in our study. Therefore,
several filter materials, which all consist of alpha-cellulose (Sartorius filter paper,
Whatman filter paper, and Schleicher& Schuell filter paper) were tested.
In comparison, all three filter matrices showed a prominent peak at retention time of
around 6 minutes. Therefore, they may interfere with the internal standard, which
typically appeared at this retention time. Since all three filters are composed of high
levels of alpha-cellulose it can be assumed, that the interfering signal may possibly
be alpha-cellulose (or fragments thereof), which is dissolved during sample prepa-
ration.
However, only the Whatman and the Schleicher& Schuell filters additionally showed
a relatively high background noise, which would later complicate quantitative de-
tection of low amounts of gemcitabine. Therefore, we decided to use the Sartorius
filter papers for further studies.
4.3.2 Influence of pH Value of Filter Extraction Solution
The next crucial step was the extraction of gemcitabine from the filter material of
the wipe sample. In order to achieve a quantitative extraction of gemcitabine from
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the filter material, the pH value of the filter extraction solution is essential. Gemc-
itabine is a weak base with a pKb of 10.4, the corresponding acid having a pKa of
3.6. It typically shows a poor stability in moderate alkaline and extreme acidic en-
vironments [26]. Therefore, three different aqueous solutions, acidic water at pH
3, deionized water at pH 6 and alkaline water at pH 9, were evaluated. Since the
mean peak area represents the amount of the analyte in the sample, the mean peak
areas of gemcitabine were analyzed in order to choose the optimal pH value of the
extraction solution. Our study clearly demonstrated that different pH values of the
filter extraction solution have no impact on the mean peak area of analyzed gemc-
itabine and therefore no effect on filter extraction process of gemcitabine within the
range of pH 3-9. The slight deviations between the solutions can be attributed to
measurement artefacts. We decided to use acidified water with a pH value of 3 for
further extraction steps, since the following solid phase extraction requires an acidic
solution for loading the analyte onto the column.
4.3.3 Extraction of Gemcitabine in Wipe Samples by Solid Phase Extrac-
tion (SPE)
To isolate gemcitabine from possible contaminants in the wipe sample a SPE was
performed prior to each chromatographic analysis. Additionally, the SPE, which
enables a concentration of the sample, may significantly increase the sensitivity of
the HPLC-method. SPE makes use of the affinity between the chemical surface of
a packed column and an analyte to retain the latter. Thus, several washing steps
can be performed, to purify the bound analyte of any impurities and subsequently
concentrate it. The bond between the analyte and the surface of the column is sub-
sequently reversed (in this instance via a pH change of the solvent), and the analyte
can be eluted freely.
To test the efficiency of the SPE, recovery of gemcitabine before and after SPE was
determined. The absence of gemcitabine was additionally confirmed in the washing
solutions, which verifies that no analyte losses occur during washing.
A total recovery of gemcitabine after SPE of 98.32 % was achieved. Thus, the SPE
is perfectly suitable as purification method for our analyte, since no analyte loss oc-
curred during the purification and isolation process via SPE.
4.3.4 Influence of pH Value of SPE Eluate
Next, the influence of the pH value of the sample on chromatographic parameters
after SPE was investigated. Since gemcitabine and 2dC both have primary amino
groups Figure 4.2, which can be protonated, an acidic solvent transforms both sub-
stances into their ionized form. Positively charged molecules show a higher affinity
to the negatively charged ion-pairing reagent sodium octanesulfonate, and the corre-
sponding ion pair has increased lipophilicity and affinity to the stationary phase. A
comparison of the peak symmetry and peak area of gemcitabine and internal stan-
dard at different pH values was evaluated. Our results clearly demonstrate that
different pH values had a crucial impact on both peak symmetry and mean peak
area. We assumed that incomplete ionization can have a substantial impact on peak
36 Chapter 4. Discussion
symmetry and area. A high pH value of pH 5 and 7 leads to poor ionization of gem-
citabine and 2dC, thereby reducing mean peak area and worsening peak symme-
try. The 2dC peak appears to be deformed, possibly by the hydrophile gemcitabine,
which elutes at a lower retention time and overlaps with the area of the internal
standard.
In an extremely acidic environment at pH 1, gemcitabine is not stable and thus de-
tection is poor [26]. The optimal pH value was discovered to be at a pH value of
3. At pH 3, both gemcitabine and 2dC showed a distinct signal with a peak sym-
metry between 0.9 and 1.1. However, a minor tailing effect is visible. Consequently,
for further method development, the pH of the SPE eluate was adjusted to 3 before
injection onto the column.
4.4 Outpatient Clinic Surface Measurements
After finalisation of our HPLC Method and Standard Operation Procedure, real wipe
samples were taken at an outpatient clinic for oncology. Standard cytostatic therapy
regimes for cancer include a variety of chemotherapeutic drugs, i.e. taxanes, platin
derivates, alkylating agents. In this study, it should be verified whether the devel-
oped method for gemcitabine is applicable in an environment full of antineoplastic
chemicals that could act as potential contaminants. To test our developed method for
the detection of gemcitabine in wipe samples under real work conditions, outpatient
clinic surface measurements were performed at various sampling sites. Compared
to the samples analyzed under laboratory conditions, the gemcitabine peak in real
life samples showed no interference with other cytostatic drugs or surface contami-
nants. The peak for gemcitabine was always symmetrical and distinct, with no other
substances influenced detection or sensitivity. Considering that the prospect of the
presence of other cytostatic drug in an outpatient setting is high, it can be assumed
that our method and preanalytics facilitate a selective detection of gemcitabine un-
der real world conditions. Thus, our developed method is applicable at real working
conditions and we could successfully detect gemcitabine in outpatient clinics.
As expected, the highest concentration of the analyte was detected directly at the
preparation site in the isolator. Besides that, traces of gemcitabine could also be de-
tected in the patient recreation area and the patient bathroom floor. Gemcitabine
is a hydrophile antineoplastic drug that is almost quantitatively eliminated by the
kidneys either as unmetabolized substance (~10 %) or as uracil metabolite 2’,2’-
difluoro-deoxyuridine (dFdU) [23]. Therefore, a possible contamination in the pa-
tient restrooms may be likely. Our finding confirms these results. Additionally, the
patient recreation area was also tested positive for gemcitabine, which could be an
indication for unsafe practices during application of chemotherapy by staff as well
as contamination of surfaces by skin contact to furniture. Similar findings have been
published before in the study of Kopp et. al. [30] No traces of gemcitabine were
found in work benches, printer, floors, and the reception desk of the outpatient clin-
ics. Either these location sites are not contaminated with Gemcitabine or the devel-
oped detection method in wipe samples with an LOD of 0.091 µg/ml is not sensi-
tive enough to detect traces of gemcitabine. To determine traces of gemcitabine or
to exclude any contamination with gemcitabine on those sites, a mass spectrometry-
based method with higher sensitivity could be applied.
Work place contamination with cytostatic drugs is a well known problem in clinics
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and private practices. However, analytical studies about workplace contaminations
in outclinic patient settings is rather scarce. A summary of the recent studies about
workplace contamination with gemcitabine in outpatient clinic settings using wipe
samples is listed in Table 4.1. Kopp et al., applied a LC-MS/MS method for the de-
tection of several antineoplastic drugs including gemcitabine on workplaces using
wipe samples [30]. They demonstrated that around 60 % of forty assessed institu-
tions were tested positive for the contamination of one or more wipe samples, con-
taining one or more of the following agents (5-fluorouracil, platinum, gemcitabine,
ifosfamide, methotrexate, docetaxel, paclitaxel). For gemcitabine, in 64 % of the sam-
ples contamination was detected, with a median of 1.2 pg/cm2. Since our method
is based on UV detection and Kopp et al. used a MS/MS based detection method,
their LOD is lower compared to our developed method. Hence our method is only
suitable for higher concentrations of gemcitabine. The specific distribution of gemc-
itabine contaminated samples also varied from our findings. Whereas our outpatient
clinic samples tested positive in the preparation area for antineoplastic agents (cyto-
static isolator) and showed a high sample contamination of 1326 pg/cm2, the most
contaminated sampling site in other clinics was the floor, with a 75th percentile of
88.6 pg/cm2. Whereas in our real samples traces of gemcitabine were detectably in
the patient restrooms, Kopp et al. could not detect any contamination of gemcitabine
in the patient restrooms.
In the ESOP study, wipe samples for the contamination of cytotoxic drugs in 15 Eu-
ropean hospitals were tested and measured by LC/MS/MS. Measurable amounts of
at least one agent were detected on sampled surfaces in each hospital. The highest
level of drug contamination was detected on isolators and floors (in pharmacies and
wards) as well as the armrests of patient’s chairs. These findings are in accordance
with our results [66].
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LC/MS/MS,[66] 0.003 / 171 Hospitals (n=15)









Antineoplastic drugs such as gemcitabine play a crucial role in cancer therapy and
are widely used in clinics and outpatient clinical settings.
Since a vast majority of antineoplastic drugs are classified as carcinogenic, mu-
tagenic and teratogenic for humans, a minimization of contamination with antineo-
plastic drugs such as gemcitabine is essential to reduce health risks for employees in
clinics and outclinic patient settings. The aim of this study was to develop a sensitive
HPLC method for the detection of low levels of gemcitabine in wipe samples. Wipe
sampling enables the assessment of exposures caused by surface contamination and
can be also used to verify the effectiveness of decontamination procedures. In this
thesis, a wipe sampling procedure coupled to RP-HPLC was developed for the de-
termination of gemcitabine. The procedure includes a prior solid phase extraction
process for purification and concentration of gemcitabine in the wipe sample. Vari-
ous chromatographic parameters as well as the purification process were tested and
further optimized.
Finally, the developed method was successfully applied for the determination of sur-
face contamination in an outpatient clinical oncology setting.
LC-MS/MS is a highly sensitive method, which enables the detection of low amounts
of drug contamination. However, monitoring by HPLC-UV is a cheap, broadly ap-
plicable, and robust technique, which might be especially beneficial for third world
countries. Future work should be focused on the monitoring of other relevant anti-
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